Physician profile
Solicia Smith
NPI 1336809920
$2,252.07
in general payments reported to CMS, 2019-2025
18 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $689 · 2023: $650 · 2024: $572 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.07 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.58 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $524.14 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $329.52 | 2022-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $203.29 | 2022-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $131.75 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $125.63 | 2022-2023 | Mounjaro |
| Pfizer INC. | $117.51 | 2022-2025 | |
| Exact Sciences Corporation | $68.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $41.47 | 2023 | Austedo, Austedo Xr |
| Silk Road Medical, INC. | $22.79 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Tolmar, INC. | $20.78 | 2025 | Jatenzo |
| Axsome Therapeutics, INC. | $19.40 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $19.17 | 2022 | |
| Corcept Therapeutics | $19.12 | 2025 | Korlym |
| Amgen INC. | $17.94 | 2023 | Repatha, Otezla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $15.47 | 2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solicia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.